Legis Daily

Drug Price Transparency Act

USA116th CongressHR-2087| House 
| Updated: 5/21/2019
Lloyd Doggett

Lloyd Doggett

Democratic Representative

Texas

Cosponsors (1)
Vern Buchanan (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Drug Price Transparency Act This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 4, 2019
Introduced in House
Apr 4, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2019
Referred to the Subcommittee on Health.
Apr 5, 2019
Referred to the Subcommittee on Health.
May 21, 2019
Subcommittee Hearings Held.
  • April 4, 2019
    Introduced in House


  • April 4, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 4, 2019
    Referred to the Subcommittee on Health.


  • April 5, 2019
    Referred to the Subcommittee on Health.


  • May 21, 2019
    Subcommittee Hearings Held.

Health

Related Bills

  • HR 116-1570: Removing Barriers to Colorectal Cancer Screening Act of 2020
  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • S 116-3129: Lower Costs, More Cures Act of 2019
  • HR 116-2113: Prescription Drug STAR Act
  • S 116-2051: Strengthening Average Sales Price Reporting Act of 2019
  • HR 116-19: Lower Costs, More Cures Act of 2019
Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightConsumer affairsHealth care costs and insuranceHealth information and medical recordsInsurance industry and regulationMedicarePrescription drugsRetail and wholesale trades

Drug Price Transparency Act

USA116th CongressHR-2087| House 
| Updated: 5/21/2019
Drug Price Transparency Act This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 4, 2019
Introduced in House
Apr 4, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2019
Referred to the Subcommittee on Health.
Apr 5, 2019
Referred to the Subcommittee on Health.
May 21, 2019
Subcommittee Hearings Held.
  • April 4, 2019
    Introduced in House


  • April 4, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 4, 2019
    Referred to the Subcommittee on Health.


  • April 5, 2019
    Referred to the Subcommittee on Health.


  • May 21, 2019
    Subcommittee Hearings Held.
Lloyd Doggett

Lloyd Doggett

Democratic Representative

Texas

Cosponsors (1)
Vern Buchanan (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • HR 116-1570: Removing Barriers to Colorectal Cancer Screening Act of 2020
  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • S 116-3129: Lower Costs, More Cures Act of 2019
  • HR 116-2113: Prescription Drug STAR Act
  • S 116-2051: Strengthening Average Sales Price Reporting Act of 2019
  • HR 116-19: Lower Costs, More Cures Act of 2019
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightConsumer affairsHealth care costs and insuranceHealth information and medical recordsInsurance industry and regulationMedicarePrescription drugsRetail and wholesale trades